500 sales reps will get Novo’s obesity dream up and running
Novo Nordisk has a clear strategy for how the group will conquer the US market for obesity drugs. The sales team is already in the field and several hundred nurses are engaged in training activities, but a number of barriers make the job of cultivating the market tricky.
BY BENJAMIN WERNER CHRISTENSEN
The market could potentially be huge, but it is also largely uncultivated. Consequently, Novo Nordisk makes no bones about the fact that its American obesity dream remains a dream for now and in years to come. The Danish-based drug group is not likely to have a new blockbuster in its portfolio on this market in the first couple of years.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo launches obesity drug in the US
For abonnenter
Novo wins approval of obesity drug in Europe
For abonnenter
Novo’s obesity contender Saxenda wins US approval
For abonnenter
